Background Growth failure is common among children with chronic kidney disease (CKD). We examined the relationship of growth parameters with glomerular filtration rate (GFR), CKD diagnosis, sex and laboratory results in children with CKD. Methods Baseline data from 799 children (median age 11.0 years, median GFR 49.9 mL/min/1.73 m 2 ) participating in the Chronic Kidney Disease in Children Study were examined. Growth was quantified by age-sex-specific height, weight, body mass index (BMI-age), and height-age-sexspecific BMI (BMI-height-age) standard deviation scores (SDS). Compared to those with a serum bicarbonate (CO 2 ) level of ≥22 mEq/L, children with CO 2 of <18 mEq/L had a height SDS that was on average 0.67 lower [95 % confidence interval (CI) −0.31 to −1.03]. Only 23 % of children with a height SDS of ≤−1.88 were prescribed growth hormone therapy. Forty-six percent of children with glomerular CKD were overweight or obese (BMI-height-age ≥85th percentile). Conclusions Growth outcomes in a contemporary cohort of children with CKD remain suboptimal. Interventions targeting metabolic acidosis and overcoming barriers to recombinant human growth hormone usage may improve growth in this population.
Introduction
Severe growth impairment is highly prevalent among children with chronic kidney disease (CKD), occurring in up to 35 % of this population prior to progression to end-stage renal disease [1] [2] [3] . Beyond facing serious psychosocial and medical challenges [4, 5] , children with CKD complicated by severe growth failure experience excessive mortality [6, 7] . Specifically, children initiating dialysis with a height of <1st percentile for age-sex have a twofold higher risk of death than children with preserved height [8] , emphasizing the importance of optimizing overall care and, in turn, growth during the early stages of CKD. The etiology of growth failure in CKD is multi-factorial and includes age at CKD onset, residual renal function, metabolic derangements, renal osteodystrophy and abnormalities of the growth hormoneinsulin-like growth factor-1 axis [9] [10] [11] . The safety and efficacy of recombinant human growth hormone (rhGH) in children with CKD-associated growth failure is proven [12] and despite the availability of treatment guidelines [2] , rhGH remains underutilized in this population [1] . The principal aim of this study was to both describe and identify clinical correlates of growth characteristics [height, weight and body mass index (BMI)] in a large cohort of children with mild to moderate CKD. To achieve this, we drew upon the baseline data from the Chronic Kidney Disease in Children (CKiD) study.
Materials and methods

Study design and population
From January 2005 through to May 2013, 837 children with mild to moderate CKD have been enrolled in the CKiD study, a multicenter, prospective cohort study comprised of 53 tertiary care pediatric nephrology programs across the USA and Canada. Details of the CKiD Study design have been previously published [13] . The study design and conduct for CKiD was approved by an Institutional Review Board at each of the 53 participating centers. Height and weight were determined as the mean of two independent measurements using the stadiometer and standing scale. Age-sex-specific height, weight and BMI (BMI-age) standard deviation scores (SDS) were calculated using U.S. Centers for Disease Control and Prevention (CDC) growth charts with U.S. normative data [14] ; SDS indicate the number of standard deviations the participant is above (positive SDS) or below (negative SDS) the expected mean value for their age and sex. Current clinical practice guidelines recommend that the BMI be expressed relative to height-age in children with CKD [15] . Accordingly, the height-age-sex-specific BMI (BMI-height-age) SDS was also calculated by using the age at which the child's observed height would be at the 50th percentile for height. For children with height deficits, height-age will be less than the true chronological age and therefore tend to yield a BMIheight-age SDS that is greater than the BMI-age SDS, particularly in children aged >5 years. Because the CDC provides height-ages for children aged 24-240 months, when calculating BMI-height-age SDS scores we excluded 36 boys and 31 girls who had a height below the median for a 2 year old or above the median of a 20 year old for their gender. Pubertal (Tanner) stage was obtained by physician assessment. Underlying CKD diagnosis was determined by the site nephrologist and duration of disease was obtained by parental report. Plasma disappearance of iohexol (GE Healthcare, Amersham Division, Princeton, NJ) was used to measure glomerular filtration rate (GFR) (iGFR), details of which have been previously published [16] . Serum bicarbonate (CO 2 ), phosphate and albumin were centrally measured using an enzymatic method on the Bayer Advia 2400 analyzer (Siemens Diagnositics, Tarrytown, NY). Inflammation was assessed centrally via wide-range C-reactive protein (CRP). Complete blood counts were measured locally.
The baseline CKiD visit served as the unit of analysis. Of the 837 children enrolled between January 2005 and May 2013, data were available for GFR, height SDS and weight SDS for 799 (95 %) children. The baseline height SDS was missing in 15 (2 %) children, and the baseline weight SDS was missing in one child (<1 %). In these cases, we used height and weight SDS from the next available visit. Furthermore, baseline iGFR could not be determined in 60 (8 %) children; in these instances, we used published equations to estimate GFR [17] . For 749 (94 %) children, complete data were available on CO 2 , hemoglobin, albumin and phosphate from the primary analyses of laboratory markers. In 109 children (15 % of 749), data on laboratory markers at the second visit were used in place of missing data at the baseline visit. Because CRP was available in only 59 % of participants, we did not include it in our primary multivariate analyses.
Statistical analyses
Median and interquartile ranges (IQR) were used to summarize continuous characteristics; percentages were used to summarize categorical characteristics. Overall differences between two groups (>2 groups) with respect to median values of continuous characteristics were assessed using Wilcoxon rank sum tests (Kruskal-Wallis tests). The overall association between categorical variables was assessed using either Pearson χ 2 tests or Fisher's exact tests. Trends in median age-sexspecific height and weight SDS across age categories were assessed using the Jonckheere-Terpstra test. Linear regression was used to quantify the association between both age-sexspecific height and weight SDS and GFR in four sex-CKD diagnosis strata. Multivariable linear regression models were used to quantify the relationship age-sex-specific height and weight SDS had with laboratory markers of CO 2 , hemoglobin, albumin and phosphate, while controlling for sex, CKD diagnosis, rhGH usage and GFR. Categorizations of laboratory markers were based on clinically relevant values. Two sided P values of <0.05 were considered to be statistically significant.
Results
Cohort characteristics
Demographic and clinical characteristics of the 799 children are shown in Table 1 . The study population had a median age of 11.0 year; 63 % were male and 67 % were Caucasian. The median baseline GFR was 49.9 mL/min/1.73 m 2 (IQR 36.8-66.9). Non-glomerular diseases accounted for 75 % of the underlying diagnoses (see footnote to Table 1 Age-sex-specific height and weight SDS by sex and age Descriptive statistics for age-sex-specific height SDS by sex and eight age strata are displayed in Table 2 . Overall, females (median height SDS −0.68; IQR −1.46 to 0.13) had a greater height deficit than males (median −0.49; IQR −1.30 to 0.24), although the difference was not statistically significant (P=0.065). Males aged <5 years had a significantly greater height deficit than males aged ≥5 years (median height SDS−0.71 vs. −0.44; P=0.029). Of note, of the 82 males who were aged <5 years, only four had glomerular disease. Among females, the distribution of age-sexspecific height SDS was comparable across age strata. Table 3 shows the descriptive statistics for age-sex-specific weight SDS by sex and age. Overall, males (median 0.06; IQR −0.78 to 0.95) and females (median −0.06; IQR −0.92 to 0.97) had similar weight SDS; they differed significantly only between 9 and <11 years of age. Higher weight SDS was associated with older ages among both males (P trend <0.001) and females (P trend <0.001).
Age-sex-specific height SDS by primary CKD diagnosis and renal function Compared to children with non-glomerular CKD, the median age-sex-specific height SDS of children with glomerular CKD was significantly higher (−0.33 vs. −0.62; P=0.003). The median age-sex-specific height SDS of females with glomerular disease (−0.25; IQR −1.06 to 0.58), males with glomerular disease (−0.49; IQR −1.14 to 0.35) and males with non-glomerular disease (−0.49; IQR −1.33 to 0.22) were similar (P=0.150). The median age-sex-specific height SDS of females with non-glomerular CKD (−0.83; IQR −1.62 to −0.02) was significantly lower than that of each of the other three groups (P<0.001). IQR, Interquartile range a Hispanic ethnicity data missing for 11 children; Tanner Stage missing for 11 children; data on age-sex-height-specific body mass index (BMI) standard deviation score (SDS) missing for 67 children, data on chronic kidney disease (CKD) duration missing for 7 children with glomerular CKD and 13 children with non-glomerular CKD b Age-sex-specific and age-sex-height-specific SDS using U.S. Centers of Disease Control and Prevention growth charts with U.S. normative data c Glomerular diagnoses (N=203): focal segmental glomerulosclerosis (31 %), hemolytic uremic syndrome (19 %), systemic immunological disease (10 %), familial nephritis (7 %), chronic glomerulonephritis (7 %), other (26 %) d Non-glomerular diagnoses (N=596): obstructive uropathy (24 %), aplastic/hypoplastic/dysplastic kidneys (23 %), reflux nephropathy (19 %), polycystic kidney disease (autosomal recessive) (4 %), renal infarction (4 %), other (26 %) Given the poorer linear growth noted among children with non-glomerular CKD, particularly the girls within this group, we analyzed the relationship between GFR and age-sex-specific height SDS by both CKD diagnosis and sex. Among those with glomerular CKD, each 10 mL/min per 1.73 m 2 decrease in GFR was associated with a 0.12 (95 % CI 0.04-0.20) lower age-sex-specific height SDS in 112 males and a 0.16 (95 % CI 0.07 to 0.26) lower age-sex-specific height SDS in 91 females. Similarly, in the 393 males and 203 females with non-glomerular CKD, a 10 mL/min per 1.73 m 2 decrease in GFR was associated with an average decrease in height SDS of 0.14 (95 % CI 0.09-0.19) and 0.12 SDS (95 % CI 0.05-0.20), respectively. The effect of GFR on age-sex-specific height SDS was similar in all four sex-CKD diagnosis strata.
Weight and BMI SDS by primary CKD diagnosis and renal function
Compared to children with non-glomerular CKD, the median age-sex-specific weight SDS of children with glomerular CKD was significantly higher (0.53 vs. −0.13; P<0.001); this relationship was observed in both males (0.24 vs. −0.05; P<0.001) and females (0.63 vs. −0.32, P<0.001). Expressed as BMI-age, 18 % of children with glomerular CKD were overweight and 27 % were obese (median SDS 0.91; IQR −0.10 to 1.73); both of these values are higher than the corresponding percentages observed in children with non-glomerular CKD (15 % overweight and 15 % obese; median SDS0.31; IQR −0.41 to 1.19). Expressed as BMI-height-age, 17 and 29 % of children with glomerular CKD (median SDS 0.88; IQR 0.18-1.76) and 16 and 16 % of children with non-glomerular CKD (median SDS 0.46; IQR −0.26 to 1.29) were overweight and obese, respectively. Given the trend of increased weight SDS with older age in this cohort and the expected changes in body composition during childhood (BMI declining after birth and generally increasing after age 5 years), we examined BMI-height-age of children aged >5 years and found that 18 and 29 % of children with glomerular CKD (N=174; median SDS0.88; IQR 0.18-1.76) and 17 and 18 % of children with non-glomerular CKD (N =465; median SDS 0.49; IQR −0.25 to 1.37) were overweight and obese, respectively. We analyzed the relationship between GFR and agesex-specific weight SDS by both CKD diagnosis and Usage of rhGH, steroids and enteral feeding Nine percent of the entire cohort and 23 % of children with severe short stature (height SDS ≤ −1.88) were prescribed rhGH. Among children with non-glomerular disease, the percentage of girls (11 %) and boys (11 %) prescribed rhGH was similar. Likewise, the percentage of girls (4 %) and boys (3 %) with glomerular CKD who were prescribed rhGH was similar. When compared to children with glomerular disease, children with non-glomerular CKD were significantly more likely to be prescribed rhGH (P<0.001). Of the children with severe short stature, the percentage prescribed rhGH was similar between girls (23 %) and boys (24 %). Furthermore, the percentage of children with severe short stature prescribed rhGH was similar among glomerular and non-glomerular groups, regardless of gender (P=0.569). Within 30 days of the baseline visit, steroids were prescribed in 27 % of children with glomerular CKD compared with 1 % of children with non-glomerular causes (P<0.001). Among those with glomerular CKD, the median height SDS of children who were prescribed steroids daily (−0.28; IQR −0.69 to 0.90; N=29), less than daily (−0.11,;IQR −1.06 to 0.51; N=26) and not prescribed steroids (−0.46; IQR −1.18 to 0.24; N=148) was similar (P=0.348). The median weight SDS among glomerular children prescribed steroids daily, less than daily and not prescribed steroids was 1.07 (IQR 0.04-2.23), 1.18 (IQR 0.19-2.10) and 0.28 (IQR −0.43 to 1.38), respectively. Glomerular children prescribed steroids daily or less than daily had significantly higher weights than children who were not prescribed steroids (P=0.007).
Four percent of the cohort were provided enteral feeding at baseline, and there was no significant difference in enteral feeding by diagnosis or gender. Surprisingly, of the children receiving enteral feedings, only 17 % were aged <3 years and 31 % were aged <5 years. Those receiving enteral feeding experienced significantly greater deficits in both the height (P<0.001) and weight (P<0.001) SDS. Specifically, children on enteral feedings had median height and weight SDS of −1.34 (IQR −2.00 to −0.44) and −0.86 (IQR −2.06 to 0.22) respectively, whereas children that were not receiving enteral feedings had a median height and weight SDS of −0.52 ( IQR −1.31 to 0.23) and 0.05 (IQR −0.77 to 0.98), respectively.
Age-sex-specific height and weight SDS and laboratory parameters Using two multivariate linear regression models, we quantified the relationship that age-sex-specific height SDS and weight SDS had with serum CO 2 , hemoglobin, albumin and phosphate while controlling for sex, CKD diagnosis, rhGH usage and GFR (Table 4) . Baseline growth characteristics were worse in children with metabolic acidosis. Specifically, children with a serum CO 2 level of <18 mEq/L had height and weight SDS that were on average 0.67 (95 % CI −0.31 to −1.03) and 0.40 lower (95 % CI −0.02 to 0.81), respectively, than children with a serum CO 2 level of ≥22 mEq/L. Children with a serum CO 2 level of <18 mEq/L had an average height SDS that was significantly lower than children with a CO 2 level of ≥18 to <22 mEq/L (P=0.006), but there was no significant difference in weight. Anemia, low serum albumin, and elevated serum phosphate were not significantly associated with height or weight SDS. In the two multivariate analyses that included CRP and all of the variables included in Table 4 , among the 443 children for whom CRP data were available, we did not find any signficant differences in height and weight SDS in children with a CRP level of >10 mg/L compared to children with a CRP level of ≤10 mg/L (normal range). Only 1 % of the cohort had hyponatremia (serum Na <135 mEq/L), and therefore serum sodium was not included in this analysis.
Discussion
The CKiD patient population is particularly well studied in terms of GFR measurements, accurate evaluations of height and weight and regular metabolic assessments. As such, these patients have provided the opportunity to expand on the data pertaining to growth in patients with CKD that have previously been published. Deficits in height were a frequent finding among our large cohort of North American children with mild to moderate CKD: 12 % of the children in this analysis had severe short stature (height SDS ≤−1.88) at the time of their baseline CKiD visit. Though alarming, this compares favorably with the linear growth of children enrolled in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) chronic renal insufficiency registry during the decade preceding January 2004 when 31 % of children with an estimated GFR >25 mL/min/ 1.73 m 2 had a height SDS of <−1.88 [18] . Previous studies have identified children with CKD during infancy and early childhood to be particularly vulnerable to growth failure [18, 19] , and a recent study has demonstrated abnormal birth history to be associated with poorer growth in children with both glomerular and non-glomerular disease [20] . In the CKiD cohort, children with non-glomerular disease, encompassing congenital disorders of the genitourinary tract, had lower height and weight SDS than children with glomerular disease; this outcome likely reflects the longer duration of disease experienced by children with nonglomerular disease. Older age was associated with improved height outcomes among boys, but not among girls. In fact, although gender has not previously been associated with worse growth outcomes [18, 21] , our results identify gender as an important correlate of baseline growth; girls with nonglomerular disease proved to be the most severely impacted with respect to linear growth. The overall difference in stature we noted between children with glomerular and nonglomerular CKD was, in fact, due to the greater deficit in stature of girls with non-glomerular CKD. The factors associated with worse height outcomes in these girls are unclear. Girls with non-glomerular CKD and severe short stature did not have a higher prevalence of moderate to severe metabolic acidosis nor were a lower percentage prescribed rhGH compared to other children with severe short stature; however, because only 12 % of the cohort had severe short stature it is difficult to better explain these null findings. It is possible that although the percentage of girls and boys with nonglomerular disease prescribed rhGH was similar, adherence among these girls may have been lower given societal acceptance and potential subjective satisfaction of shorter stature among girls. When adherence to rhGH was examined in children with primarily non-CKDrelated growth disorders (<5% with CKD), adherence was found to be significantly better among boys in one study [22] but not different among genders in another [23] . It is notable that the height of boys with nonglomerular disease was comparable to that of boys with glomerular disease, despite the significantly longer duration of disease experienced by these boys. This finding may be, in part, attributable to a higher percentage of boys with non-glomerular disease prescribed rhGH (11 %) when compared to children with glomerular disease (3-4 %).
Consistent with the findings of previous studies, our results demonstrate the level of estimated renal function to be an important independent variable correlating with growth outcomes in children with CKD [18, 24, 25] . What has not previously been published is our finding that for each 10/ mL/min/1.73 m 2 decrease in GFR, there was an average decrease of 0.14 SDS in height for the overall cohort (and an average decrease of 0.12 SDS after excluding those who were prescribed rhGH); the quantification of this association will be further studied longitudinally in the CKiD cohort.
A recent analysis of the CKiD cohort identified participants with mild-moderate CKD to be at increased risk for a variety of laboratory abnormalities, including metabolic acidosis [25] . Among children with normal renal function and renal tubular acidosis, metabolic acidosis has been clearly associated with growth retardation, which improved with alkali therapy [26, 27] . The current National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines recommend providing alkali supplementation to maintain serum CO 2 at ≥20 mEq/L among children aged <2 years and at ≥22 mEq/L in children aged >2 years [14] . Multivariate analysis of the NAPRTCS database did not reveal an association between metabolic acidosis and severe growth delay [18] . In contrast, although mild metabolic acidosis (CO 2 ≥18 to <22 mEq/L) was not associated with worse growth outcomes in CKiD, moderate to severe metabolic acidosis (CO 2 <18 mEq/L) was associated with a significantly lower height SDS. The association of metabolic acidosis and poorer height outcomes found in CKiD but not in NAPRTCS may be due to differences in data analysis, particularly with respect to the height outcome chosen. The NAPRTCS evaluated the association of metabolic acidosis and severe short stature (height SDS <−1.88) as a a binary outcome, whereas our analysis evaluated the effect of metabolic acidosis on height SDS as a continuous outcome. Remarkably, two-thirds of children in this analysis who presented with a serum CO 2 level of <18 mEq/L were not prescribed alkali supplements. Our data would predict significant growth benefits of this inexpensive and easily administered therapy. While milder degrees of metabolic acidosis were not associated with significant differences in baseline growth, the potential for other negative consequences of metabolic acidosis, including bone disease and more progressive decline in renal function, must be considered [28] . It is notable that 77 % of children in CKiD with severe short stature were not prescribed rhGH at their baseline visit despite studies demonstrating the efficacy of rhGH therapy [12, 29, 30] , the availability of published guidelines [2] and treatment that was provided at academic medical centers. A prior multicenter study of children with CKD and height below the 5th percentile demonstrated that boys were twice as likely as girls to be treated with rhGH [31] , while in our cohort, an equal proportion of girls and boys with severe short stature were prescribed rhGH. The most commonly reported obstacles to rhGH usage include medical and psychosocial factors, secondary hyperparathyroidsim, family refusal and non-compliance [31] . Self-reported nonadherence to rhGH, as defined by missing at least one dose within 7 days, was 25 % among the CKiD cohort [32] . Furthermore, the challenges of obtaining insurance approval and anticipation of preemptive transplantation may result in a significant delay or even failure in initiating rhGH therapy. A recent study has demonstrated height gains and rhGH use to be associated with significant improvements in parent-reported physical and social functioning of children with CKD, and these results may facilitate parental acceptance of this therapy [33] . Analysis of practice patterns of pediatric nephrologists pertaining to the assessment and treatment of growth delay is currently being conducted by CKiD and may identify opportunities to increase the appropriate utilization of rhGH therapy.
Anemia has been associated with shorter stature in children with CKD, although data are limited and controversial [3, 18] . The data obtained from our large patient cohort did not reveal an association between anemia and poor growth, largely negating any further consideration of any such correlation in patients with only mild anemia. Consistent with other reports, multivariate analysis of serum albumin, phosphate and CRP also revealed no association with baseline growth outcomes in the CKiD cohort [3, 18, 24] .
Relative to deficits of stature, the weight of children participating in CKiD was generally preserved, a finding consistent with previous reports describing growth outcomes in children with CKD [34, 35] . Our analysis identified weight to be significantly associated with underlying CKD diagnosis, whereby the median weight SDS of children with glomerular CKD was higher than expected for their age and sex, and significanly higher than the weight SDS of children with nonglomerular disease. The disproportionate effect on growth parameters was associated with a high prevalence of elevated BMI-age, a known risk factor for cardiovascular disease [36] and future end-stage renal disease [37] . Thirty-three percent of the CKiD cohort was overweight or obese, similar to the prevalence reported in children and adolescents in the general population of the USA [38] , and nearly half of the children with glomerular disease were overweight (18 %) or obese (27 %). BMI varies with age and pubertal status, increasing in normal children after age 5 years due to changes in body composition and proportions. Children with CKD are short and sexually immature [25] , and thus guidelines recommend that BMI might best be expressed relative to height-age in children in this population [15] . It has been suggested that this measure more effectively compares children with CKD to healthy children of the same height and stage of sexual development [39] . The median BMI-age and BMI-height-age SDS of children with glomerular disease were similar (0.91 vs. 0.88), although the latter was higher in children with nonglomerular disease (0.31 vs. 0.46) which has not been previously reported. The difference likely relates to the longer duration of disease and shorter stature of children with nonglomerular disease. There are, of course, limitations to using BMI-height-age as an assessment of growth in children, such as when short stature is disproportionate to the degree of delay in sexual maturation or when sexual maturation is complete. In addition, BMI-height-age has not been adequately studied in children with CKD who are less than 5 years of age.
The shorter duration of CKD and higher prevalence of edema may be factors associated with the higher frequency of increased weight seen in children with glomerular disease when compared to children with non-glomerular disease. Data on steroid therapy, which was prescribed more frequently in children with glomerular disease, accounted for treatment within 30 days of the baseline visit and not prior therapy. This limitation precludes a valid assessment of the association of steroid usage and growth in this cohort, although this therapy was associated with significantly greater weight among children with glomerular disease. Data on dietary intake were not available.
Although this analysis of growth outcomes of the CKiD cohort has numerous strengths, including cohort size and accurate measurements of growth parameters and GFR, limitations must be acknowledged. This is a crosssectional analysis, and the longitudinal study of this cohort will be of great importance to determine the clinical correlates of abnormal growth and to identify potential interventions. The population enrolled may differ from the general population of children with CKD, and the data may be subject to selection bias. Furthermore, data on nutritional intake were not available for analysis and may limit the generalizability of these findings.
In summary, growth abnormalities were highly prevalent in the CKiD cohort, including a high prevalence of overweight and obesity among children with glomerular disease. Poorer linear growth was associated with moderate to severe metabolic acidosis, and the majority of children with this degree of acidosis were not on alkali therapy. Furthermore, less than 25 % of children with severe short stature were prescribed rhGH. One would predict that greater utilization of alkali therapy and rhGH to address two modifiable risk factors for growth impairment could yield improved growth outcomes. This is the first report to provide a quantitative relationship between decrement in GFR and negative impact on height outcomes. Longitudinal follow-up of the CKiD cohort will permit further evaluation of this important CKD-related parameter.
